Blue Cross Blue Shield/Blue Care Network of Michigan
Medication Authorization Request Form

Blue Cross Blue Shield Blue Care Network of Michigan

Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION		PHYSICIAN INFORMATION
Name		**Name**
ID Number		**Specialty**
D.O.B.	☐Male ☐Female	**Address**
Diagnosis		**City /State/Zip**
Drug Name	**Aralast NP, Glassia, Zemaira**	**Phone:** **Fax:**
Dose and Quantity		**NPI**
Directions		**Contact Person**
Date of Service(s)		**Contact Person** **Phone / Ext.**

STEP 1: DISEASE STATE INFORMATION

Required Demographic Information:

Patient Weight: _____*kg*

*Patient Height:*_____*ft* _____*inches*

Will the provider be administering the medication to the FEP member within the health plan's geographic service area?

❑ Yes ❑ No *If No, a prior authorization is not required through this process*.

Prior authorizations are required for FEP members that will be serviced by a provider within the health plan's geographic service area. If you are not a provider in the geographic service area, please contact the health plan for questions regarding the FEP member's benefit requirements.

Is this member's FEP coverage primary or secondary coverage?

❑ If primary, continue with question set.

❑ If secondary, **an authorization is not needed through this process. Please contact the member's primary coverage for determination of benefit and additional information.**

Site of Care:

A. At what location will the member be receiving the requested medication?

❑ Physician's office, home infusion, non-hospital affiliated ambulatory infusion center.

❑ Outpatient hospital infusion center. Please provide the name of the infusion center and rationale why the patient must receive this medication in a hospital outpatient setting. _____

_____

❑ Other. Please specify. _____

Criteria Questions:

Please select medication:	❑**Aralast NP**	❑**Glassia**	❑**Zemaira**

1. Does the patient have a diagnosis of emphysema? ❑Yes ❑No
2. Is the patient currently a smoker? ❑Yes ❑No
3. Has the patient been on this medication continuously for the last **2 months**, excluding samples? ***Please select answer below:***

❑ **NO** – this is **INITIATION** of therapy, please answer the following questions:

a. Is there documentation of alpha$_1$ antitrypsin (AAT) deficiency? ❑Yes* ❑No

If YES, was the deficiency determined by radial immunodiffusion, nephelometry, or serum AAT level? ***Answer below:***

❑ **Immunodiffusion**: What is the patient's level in milligrams per deciliter? _____ mg/dl

❑ **Nephelometry**: What is the patient's level in milligrams per deciliter? _____ mg/dl

❑ **Serum ATT level**: What is the patient's serum AAT level in micrometers per liter? _____ um/L

❑ **Other** ***(please specify)***: _____

b. Does the patient have documentation of progressive emphysema with moderate airflow obstruction evidenced by forced expiratory volume (FEV_1) of 30 to 65% of predicted value? ❑Yes ❑No

c. Does the patient have documentation of progressive emphysema and has had a rapid decline in lung function as measured by a change in FEV_1 greater than 120 milliliters per year? ❑Yes ❑No

d. Does the patient have documentation of progressive emphysema with a forced expiratory volume (FEV_1) greater than 65% predicted? ❑Yes* ❑No

If YES, does the patient have bronchiectasis with one or more severe exacerbation resulting in an emergency department (ED) visit or hospitalization within the last year? ❑Yes ❑No

❑ **YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the following question(s):

a. Has there been an elevation of the patient's AAT levels above the protective threshold? ❑Yes ❑No*

If NO, has there been a reduction in the rate of deterioration of lung function as shown by a reduction in FEV_1 rate of decline? ❑Yes ❑No

Chart notes are required for the processing of all requests. Please add any other supporting medical information necessary for our review **(required)**

Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.

☐ Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

Physician's Name	**Physician Signature**	**Date**
Step 2: Checklist	☐ Form Completely Filled Out ☐ Provide chart notes	☐ Attach test results
Step 3: Submit	**By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979**	**By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320**